Blrx stock yahoo
Oct 19, 2018 · BioLineRx (BLRX -21%) is down out of the gate this morning as investors appear disappointed with topline results from a Phase 2a clinical trial evaluating lead candidate BL-8040 plus Merck's (MRK -0.1 BLRX | BioLine RX Ltd. ADR Historical Quotes | MarketWatch